BIIB 015

Drug Profile

BIIB 015

Alternative Names: Anti-CRIPTO; Anti-Cripto mAB; Anti-Cripto-DM4; BIIB015

Latest Information Update: 08 Apr 2015

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Antineoplastics; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Jun 2011 Biogen Idec completes a phase I trial in Solid tumours in the USA (NCT00674947)
  • 28 Jan 2011 BIIB 015 is available for licensing as of 28 Jan 2011.
  • 30 Jun 2008 Phase-I clinical trials in Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top